Search results: (10000)
News Lurasidone in the Treatment of Adolescent Schizophrenia: How Does It Compare with Other Atypical Antipsychotics?
A meta-analysis of 13 studies comparing lurasidone with other atypical antipsychotics in monotherapy for adolescent patients with schizophrenia evaluated the effectiveness of the treatment, the rate of weight gain, and the frequency of medication discontinuation for each modality.
News Transition from Risperidone to Lurasidone and Adjustment of Metabolic Profile in Patients with Stable Schizophrenia
Patients with schizophrenia have a higher risk of cardiometabolic diseases compared to the general population, which is further increased by certain antipsychotics. A recently published post hoc analysis assessed, among other things, the metabolic parameters of patients who switched from risperidone therapy to lurasidone.
News Brigatinib in Patients with ALK+ NSCLC – Final Results of the J-ALTA Clinical Study
At this year's American Society of Clinical Oncology (ASCO) conference held in Chicago in early June 2022, the final results of the J-ALTA clinical study were presented. So how did brigatinib perform in the treatment of patients with ALK-positive NSCLC who were refractory to alectinib?
News Impact of Depth of Treatment Response on Outcomes of ALK+ NSCLC Treatment with Brigatinib and Crizotinib
Brigatinib inhibits anaplastic lymphoma kinase (ALK) and its notable advantage is its strong effect in patients who have developed resistance during treatment with other ALK inhibitors. It has demonstrated efficacy in patients with ALK+ non-small cell lung cancer (NSCLC) who are refractory to crizotinib as well as in ALK+ NSCLC not previously treated with an ALK inhibitor. Post hoc analysis of the ALTA-1L trial, presented as a poster at this year's American Society of Clinical Oncology (ASCO) annual meeting, addresses whether the maximum reduction in target lesions of ALK+ NSCLC treated with brigatinib or crizotinib correlates with overall survival (OS) and progression-free survival (PFS).
News Association of Low TSH Levels in Hypothyroidism Therapy with Mortality Risk
Community surveys indicate that up to 53% of patients treated for hypothyroidism have serum thyroid-stimulating hormone (TSH) levels outside the normal range at some point. The negative effect of TSH levels above the upper reference limit is well documented, but according to two recently published population studies, mortality in patients treated with levothyroxine is also increased when TSH levels are below the lower reference limit.
News Correlation of Levothyroxine Dose with Autoimmune Antibody Titer in Primary Hypothyroidism
The relationship between the level of antithyroid antibodies and the required dose of levothyroxine in substitution for autoimmune hypothyroidism is a poorly explored question. Therefore, a retrospective study of more than 300 patients was conducted, and we bring you a brief summary.
News ID 360 – Immunodeficiency in Interdisciplinary Collaboration 2022
For the second time, a two-day meeting titled "ID 360 – Immunodeficiency in Interdisciplinary Collaboration" took place, this time on March 25–26, 2022, in Prague. Several current topics were discussed during this professional event, which brings together experts who care for patients with primary or secondary immunodeficiencies. The meeting was professionally guaranteed by Prof. MUDr. Anna Šedivá, DSc., from the Institute of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital Motol in Prague.
News Current and Future Possibilities for Influencing Immune Thrombocytopenia
The possibilities for treating immune thrombocytopenia (ITP) are quite broad today, with a major advancement for many patients being the advent of thrombopoietin receptor agonists. However, for some patients, optimal treatment is still not available, and their hope lies in further research.
News Romiplostim in a Pregnant Woman − Case Report
The following clinical case demonstrates good control of resistant immune thrombocytopenia in a pregnant woman during the administration of romiplostim.
News Management of Musculoskeletal Issues in Hemophiliacs at a Glance
Musculoskeletal issues are among the most common complications of hemophilia. Prevention and early treatment are crucial, and this message is also addressed to specialists by the World Federation of Hemophilia (WFH) guidelines from 2020.
News Erlotinib in Conditions of Routine Clinical Practice
The patient population in clinical trials is always somewhat selected. Only a well-conducted analysis of real-world clinical practice data can provide a clearer picture of the efficacy and safety of a drug. Therefore, we are currently witnessing a significant development in this type of clinical research, for example, in the form of nationwide cohort studies. How did erlotinib perform in one of them for the treatment of non-small cell lung cancer?
News What can we base the decision on for the choice of initial treatment modality for CLL?
We now have a range of highly effective treatment options for patients with chronic lymphocytic leukemia (CLL). New drugs have significantly contributed to improved overall survival (OS). However, there are still questions about the most appropriate treatment regimen or criteria for choosing the initial therapeutic modality. Some of these questions are posed—and answers sought—by Professor John F. Seymour from the University of Melbourne in his recent communication.
News Update of International Recommendations for the Diagnosis and Treatment of Hereditary Angioedema from 2021
The aim of the 2021 update of the recommendations for the diagnosis and treatment of hereditary angioedema (HAE) is to help doctors answer important clinical questions: How to diagnose HAE? When and what prophylactic treatment to administer? What are the treatment goals? How do treatment of children and pregnant women differ? How to monitor disease activity, its impact, and control?
News Is Adding Fibrinogen Concentrate to Transfusion Therapy for Postpartum Hemorrhage an Effective Approach?
Significant postpartum hemorrhage can be managed with fresh frozen plasma transfusion. However, administering larger volumes is associated with several risks. The authors of the Japanese study below investigated whether fibrinogen concentrate added to fresh frozen plasma transfusions is an effective tool in reducing the need for erythrocyte concentrate and whether it helps prevent complications of intensive transfusion therapy.
News Administration of Fibrinogen Concentrate in Patients with Persistent Bleeding After Cardiac Surgery
Is the administration of fibrinogen concentrate in patients with persistent bleeding after initial cardiac surgery associated with an increased risk of thromboembolic events or death? Authors of a Swedish observational study published last year aimed to answer this question.